HIV infection is the greatest known risk factors for the development of activerntuberculosis in individuals latently infected with tuberculosis, and there is now strong evidencernfor the efficacy of prophylaxis treatment in the prevention of TB in HIV infected individuals.rnImplementation of Isoniazid PT in developing country presents several problems; therefore thisrnstudy tried to assess the IPT program implemented in the ENARP sites and its applicability inrnother VCT centers. The objective of this study was to evaluating operational aspect of INHrnprophylaxis program for Human immuno-deficiency virus positive patients in the ENARP sites.rnA crossectional study supplemented with review of available cohort data was conducted. All HIVrnpositive cohort participants, in the two ENARP sites, were includedrnOf 132 HIV positive participants 61(21.6%) were selected for INH prophylaxis program based onrnCD4 count who had less than 350 cell/mm3. Among 71(53.8%) participants who were notrnincluded in the IPT program, 13(18.3%) died, 37(52.1%) subjects were excluded due to their CD4rncount, 13(18.3%) due to recent TB treatment history and 5(7.04%) refused to participate in thernIPT program. TST were done to identify the most benefited with IPT, 44.3% were anergic andrn26.2% were positive. Of 61 participant 57.4% were completed PT, 24.6% discontinued andrn7(11.5%) subjects were on treatment during data collection. The study uptake looks appropriaternin that the risk of having TB increases with the CD4 count less than 350 cell/mm3, OR=1.12,95%rnCI (1.06-1.28) .TST induration size had significant correlation with CD4 count using linearrnregression model and Pearson correlation analysis. Except 9.8% the rest 84.4% got health carernsupport from the project to enhance adherence, 92.8% were agree on that ENARP staffs has goodrnpatient approach. And 86.6% were appreciate the service given to them and recommend to others.rnOf 61 participants 19(31.1%) missed scheduled appointment. Among 32 who completedrn5(15.6%) of them missed ingesting daily pills only for a day. And INH metabolites test werernpositive in 80.4% of study subjects. IPT doesn't have effect on CD4 count and weight usingrnWilcoxon sign rank test. Ninety-three point seven of the cost of the program spent before thernpatient starts PT. The benefit due to PT exceeded the cost of the program by 4.99 factors. Studyrnuptake looks appropriate, screening for active TB was performed as it was recommend by WHO.rnEven though different methods used to select those most benefited, it needs further evaluation.rnAdherence to treatment in the project favorably compares with other similar study. Therefore thernproject has shown the feasibility of IPT in our context.